TPM Vol. 32, No. S6, 2025
ISSN: 1972-6325
https://www.tpmap.org/

A MULTIDISCIPLINARY APPROACH TO MANAGING POLYPHARMACY AND ITS ORAL HEALTH COMPLICATIONS (XEROSTOMIA) IN THE GERIATRIC POPULATION: A COMPREHENSIVE REVIEW

NAJAH ASSAF THAAR ALOTAIBI[1], WAFA AYEDH ABBAS ALSHALAWI[1], ASHWAQ KHALID MUTHYIB ALMUTAIRI[2], SARA GHASHAM ALQAHTANI[3], MANAL HAMDAN ALDOSSARI[4], HUWIDA ABDULLAH ALDEBYAN[5], RENA SALEH ALSAIARE[6], ARWA KHALAF ALTHUBYANI[7], GHADAH ALHARBI[8]

[1]SENIOR SPECIALIST-SOCIAL SERVICE, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA
[2] SOCIAL SERVICE SPECIALIST, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA
[3] GENERAL DENTISTRY, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA
[4] SENIOR PHARMACIST, PHARMACEUTICAL SCIENCES, PHARMACOLGY, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA
[5] NURSING TECHNICIAN, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA
[6] CLINICAL BIOCHEMISTRY, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA
[7] BIOTECHNOLOGY, CLINICAL RESEARCH, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA
[8] MEDICAL LABORATORY, KING ABDULAZIZ MEDICAL CITY, RIYADH, SAUDI ARABIA

Abstract
The global population is aging at an unprecedented rate, a demographic shift that brings with it a parallel rise in the prevalence of chronic diseases and multimorbidity . This phenomenon has precipitated two converging, and often synergistic, public health challenges in the geriatric population: polypharmacy and its frequent complication, xerostomia. While often managed in separate clinical silos, these conditions are deeply intertwined, creating a cascade of adverse outcomes that diminish quality of life and place a substantial burden on healthcare systems. The convergence of these future directions restorative biotechnologies, predictive diagnostics, and integrated, accessible care models paints an optimistic picture. The management of polypharmacy and xerostomia is poised to evolve from a reactive, palliative discipline into a proactive, personalized, and potentially curative field of geriatric medicine. A fragmented approach, where a physician manages chronic diseases and a dentist treats oral symptoms independently, is proving insufficient to address the complex interplay of factors at hand. This review synthesizes the current evidence to advocate for an integrated, multidisciplinary framework as the essential standard of care for assessing and managing polypharmacy-induced xerostomia in older adults.
Key words: Multidisciplinary; Approach; Polypharmacy; Oral Health; Xerostomia; Geriatric population.

INTRODUCTION:

The Dual Burden: Defining Polypharmacy and Xerostomia in the Geriatric Context

Polypharmacy is most widely defined as the regular, concurrent use of five or more medications . However, this definition is not standardized, with some studies using a threshold as low as two or as high as 11 medications . It is crucial to distinguish between "appropriate" polypharmacy, which may be clinically indicated for managing complex, comorbid conditions like heart disease and diabetes, and "inappropriate" or "problematic" polypharmacy, which involves unnecessary drugs, incorrect dosages, or medications whose potential for harm outweighs their benefit .[1]

The prevalence of polypharmacy is exceptionally high in the geriatric population, stemming from the accumulation of treatments for multiple chronic conditions . A recent comprehensive meta-analysis estimated that nearly 40% of the elderly population worldwide is exposed to polypharmacy, with an even higher prevalence of 13.3% for hyperpolypharmacy (10 or more drugs) . This prevalence varies widely across studies and settings, from 11.5% to 62.5%, and is significantly higher in developed regions and among residents of long-term care facilities [2].

Xerostomia is the subjective sensation of a dry mouth. It is a distinct entity from hyposalivation, which is the objective,

measurable reduction in salivary flow . While the two often coexist, a patient may experience xerostomia even with normal salivary flow, suggesting that changes in saliva composition, such as reduced mucin content, can contribute to the sensation of dryness . Conversely, significant hyposalivation may be present before a patient reports symptoms; typically, salivary flow must decrease by approximately 50% before xerostomia becomes clinically evident [3].

The prevalence of xerostomia in the geriatric population is alarmingly high, affecting an estimated 30% of patients older than 65 years and up to 40% of those older than 80 years . In some populations, this figure may be as high as 50% . Critically, this is not an inevitable consequence of aging itself. While some age-related histological changes occur in salivary glands, evidence strongly indicates that the primary drivers of xerostomia in older adults are the high burden of systemic diseases and, most significantly, the use of multiple medications [4].

The Clinical and Humanistic Impact

The reduction in salivary flow and alteration of saliva's protective qualities precipitate a cascade of debilitating oral and systemic consequences, profoundly affecting both physical health and overall well-being.[5]

Oral Health Sequelae

From a dental perspective, hyposalivation represents a catastrophic failure of the oral homeostatic system. Saliva is essential for lubricating oral tissues, buffering acids produced by cariogenic bacteria, providing a reservoir of calcium and phosphate for tooth remineralization, and exerting antimicrobial effects through proteins like lysozyme and lactoferrin [6]. When this protective barrier is compromised, the oral environment becomes highly susceptible to disease. The most immediate and devastating consequence is a dramatically increased risk for rampant dental caries . This is not ordinary tooth decay; xerostomia-related caries are aggressive and often appear in atypical locations that are normally resistant, such as the cervical (gumline) areas of teeth, root surfaces exposed by gingival recession, and even the incisal edges of front teeth . Without saliva's buffering capacity, the oral pH drops and remains acidic for longer periods after carbohydrate consumption, creating an ideal environment for demineralization . Another common complication is oral candidiasis, or thrush, an opportunistic fungal infection that thrives in the absence of saliva's antimicrobial properties . This can manifest as erythematous lesions or painful, removable white plaques on the oral mucosa. The lack of lubrication also leads to difficulties with denture retention, causing discomfort, painful sores, and functional impairment for edentulous individuals [7].

Systemic Consequences

From a nursing and functional perspective, the impact of xerostomia extends far beyond the oral cavity, compromising fundamental activities of daily living. Dysphagia, or difficulty swallowing, is a primary complaint, as saliva is necessary to moisten food and form a cohesive bolus for safe passage . Patients often report needing to sip water constantly to swallow dry foods, such as crackers or bread . This difficulty in eating, combined with altered taste (dysgeusia) and oral pain or burning sensations, frequently leads to a loss of appetite, dietary restrictions, and ultimately, malnutrition and unintended weight loss. These nutritional deficiencies can exacerbate frailty and sarcopenia, increasing the risk of falls and further functional decline . Speech can also become difficult and uncomfortable as the tongue and lips stick to oral tissues without adequate lubrication . The culmination of these functional impairments—pain, difficulty eating and speaking, and altered taste—has a profound negative impact on an individual's quality of life. It can lead to social isolation, as patients may feel embarrassed to eat in public, and cause significant sleep disturbances due to the need to awaken frequently to drink water [8].

The Socioeconomic Footprint

The dual burden of polypharmacy and xerostomia imposes a considerable and escalating economic strain on healthcare systems, patients, and their families [9].

Burden on Healthcare Systems

Polypharmacy is a major driver of healthcare costs. It is directly linked to an increased risk of adverse drug events (ADEs), falls, disability, and medication nonadherence, all of which lead to greater healthcare utilization, including more frequent clinic visits, emergency department presentations, and hospitalizations. A cross-sectional study of older adults with cardiovascular disease found that polypharmacy was associated with nearly double the total annual healthcare expenditure ($19,068 for those with polypharmacy versus $8,815 for those without) . This increase was driven by both pharmacy-related costs, which were almost three times higher, and non-pharmacy expenditures . The costs associated with managing the oral sequelae of xerostomia, such as extensive dental restorations for rampant caries and treatment for oral infections, add another layer to this financial burden, though it is often underappreciated in medical cost analyses [10].

Impact on Patients, Families, and Caregivers

For patients and their families, the socioeconomic impact is multifaceted. There is a clear and concerning link between lower socioeconomic status (SES) and higher rates of polypharmacy . This is not simply a reflection of a higher disease burden; studies show that individuals with lower SES are also more likely to be prescribed potentially inappropriate medications (PIMs), independent of their comorbidities . This suggests a systemic inequity in the quality of medication management and care coordination, creating a vicious cycle where socioeconomic deprivation contributes to poorer health outcomes and greater medication burden . Patients face direct out-of-pocket costs for multiple prescriptions and for the extensive dental care required to manage xerostomia's complications, which are often not covered by medical

insurance. Furthermore, the complexity of managing multiple medications and dealing with debilitating symptoms like dry mouth places a significant strain on family members and caregivers, contributing to caregiver burnout and diminished quality of life for the entire family unit [11].

Study Rationale

The evidence overwhelmingly demonstrates that polypharmacy and xerostomia are not independent problems but a syndemic—a convergence of health crises in the geriatric population that are biologically and socially intertwined. The high prevalence of xerostomia is not an inevitable outcome of aging but a direct, and therefore modifiable, consequence of a high medication burden. A siloed clinical approach, in which a physician prescribes medications to manage systemic diseases while a dentist reactively treats the resulting oral damage, is fundamentally flawed. This model fails to address the root cause of the problem and leads to fragmented, inefficient, and often ineffective care.

Aim of the study:

The aim of this review is therefore to synthesize the evidence from diverse clinical and scientific fields to propose and substantiate a comprehensive, integrated, and multidisciplinary framework for the assessment and management of polypharmacy-induced xerostomia in the geriatric population. By demonstrating the interdependencies of pharmacy, dentistry, medicine, nursing, and social work, this review will argue that only through a collaborative, person-centered model can clinicians effectively mitigate the risks of polypharmacy, prevent its devastating oral complications, and improve the health and quality of life of older adults.

The Pathophysiological and Pharmacological Nexus

Understanding the intricate relationship between medications, age-related physiological changes, and salivary gland biology is fundamental to managing drug-induced xerostomia. This section explores the pharmacological mechanisms by which drugs cause hyposalivation, the biochemical basis of salivary gland dysfunction in both drug-induced and disease states, and the crucial role of laboratory diagnostics in elucidating the underlying etiology [12].

The Pharmacology of Hyposalivation

The increased susceptibility of older adults to drug-induced xerostomia is not a simple matter of taking more pills; it is a complex interplay between the specific properties of the drugs, age-related changes in how the body processes them, and the cumulative effect of multiple medications [13].

Key Xerostomic Drug Classes

Over a thousand medications have been associated with oral dryness, but several classes are particularly notorious for their xerogenic potential, primarily due to their effects on the autonomic nervous system . The most significant mechanism is the blockade of neural pathways that stimulate salivary secretion [14]. A summary of key drug classes is provided in Table 1.[7]

- **Anticholinergics:** This is the most prominent group of xerostomic drugs. They act as antagonists at muscarinic acetylcholine receptors, directly blocking the primary parasympathetic signal for saliva production . This class includes medications for overactive bladder (e.g., oxybutynin, tolterodine), tricyclic antidepressants (e.g., amitriptyline), first-generation antihistamines (e.g., diphenhydramine), and some antipsychotics [15].
- **Antihypertensives:** This broad category includes several drug classes with different mechanisms. Diuretics (e.g., furosemide, hydrochlorothiazide) can cause systemic dehydration and alter fluid and electrolyte balance, reducing the fluid available for saliva production . Beta-blockers (e.g., metoprolol), alpha-adrenergic agonists (e.g., clonidine), and angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril) are also frequently implicated .[16]
- **Psychotropics:** This diverse group includes many agents with xerostomic properties. In addition to the highly anticholinergic tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and sertraline, while having lower anticholinergic activity, still frequently cause dry mouth, possibly through central mechanisms or effects on serotonin and noradrenaline uptake . Benzodiazepines (e.g., diazepam, alprazolam) and opioids (e.g., oxycodone, tramadol) are also common culprits [17].
- **Sympathomimetics:** These drugs, which include nasal decongestants (e.g., pseudoephedrine) and bronchodilators (e.g., albuterol), stimulate adrenergic receptors. This leads to the production of a smaller volume of saliva that is more viscous and rich in proteins, contributing to the sensation of dryness [18].
-

Table 1: Common Xerostomic Drug Classes, Mechanisms, and Examples

Drug Class	Primary Mechanism of Xerostomia	Examples
Anticholinergics	Blockade of M3 muscarinic receptors on salivary acinar cells	Oxybutynin, Tolterodine, Amitriptyline, Diphenhydramine, Scopolamine
Antihypertensives	Diuresis/dehydration (Diuretics); Central/peripheral effects	Furosemide, Hydrochlorothiazide, Metoprolol, Clonidine, Lisinopril
Psychotropics	Anticholinergic, serotonergic, and noradrenergic effects	Paroxetine, Fluoxetine, Alprazolam, Diazepam, Haloperidol, Olanzapine

Drug Class	Primary Mechanism of Xerostomia	Examples
Sympathomimetics	Adrenergic receptor stimulation (produces viscous saliva)	Pseudoephedrine, Albuterol, Amphetamine
Opioid Analgesics	Central and peripheral opioid receptor effects	Morphine, Oxycodone, Tramadol
Antihistamines (1st Gen)	Strong anticholinergic (antimuscarinic) properties	Diphenhydramine, Chlorpheniramine

The Compounding Effect of Drug-Drug and Drug-Disease Interactions

The risk of adverse events escalates dramatically with the number of medications taken, a phenomenon driven by the compounding effects of drug-drug and drug-disease interactions . When a patient takes multiple medications with xerostomic potential—even if each has only a mild effect—their impacts can be additive or even synergistic, leading to a significant reduction in salivary flow . An older adult taking a diuretic for hypertension, a tricyclic antidepressant for neuropathic pain, and an over-the-counter antihistamine for allergies is accumulating a substantial "anticholinergic burden" that can precipitate severe hyposalivation [19].

Drug-disease interactions further amplify this risk. A patient with a pre-existing but perhaps undiagnosed systemic condition that com promises salivary function, such as Sjögren's syndrome or diabetes, has a diminished salivary reserve . The introduction of even a single xerostomic medication can be enough to push them from a subclinical state into overt, symptomatic xerostomia . Furthermore, common geriatric diseases like chronic kidney disease directly impact pharmacokinetics, reducing drug clearance and prolonging exposure to xerogenic agents, thereby intensifying their adverse effects [19].

The Biological Basis of Salivary Gland Dysfunction

Saliva production is a complex neuroglandular process. Understanding its cellular and molecular underpinnings is key to appreciating how both drugs and systemic diseases disrupt this vital function [20].

Cellular Mechanisms of Drug-Induced Xerostomia

The primary driver of watery saliva secretion is the parasympathetic nervous system . The process begins when the neurotransmitter acetylcholine (ACh) is released from nerve terminals and binds to M3 muscarinic receptors, a type of G-protein-coupled receptor (GPCR), on the basolateral membrane of salivary acinar cells . This binding event triggers a crucial intracellular signaling cascade:[21]

1. The activated GPCR stimulates the enzyme phospholipase C (PLC) .
2. PLC cleaves a membrane lipid, phosphatidylinositol 4,5-bisphosphate (PIP_2), into two second messengers: inositol 1,4,5-trisphosphate (IP_3) and diacylglycerol (DAG) .
3. IP_3 diffuses to the endoplasmic reticulum (ER) and binds to IP_3 receptors, causing the release of stored calcium (Ca^{2+}) into the cytoplasm.
4. This initial spike in intracellular Ca^{2+} concentration, coupled with a subsequent influx of extracellular Ca^{2+} through store-operated calcium entry (SOCE) channels, activates chloride and potassium ion channels .
5. The resulting ion flux creates an osmotic gradient that drives water movement through aquaporin-5 (AQP5) water channels, which translocate to the apical membrane, leading to the secretion of fluid into the salivary duct.

Systemic Diseases Contributing to Xerostomia and Their Biochemical Profiles

Beyond medications, several systemic diseases common in the elderly directly impact salivary gland function, each with a distinct pathophysiology and biochemical signature [22].

- **Sjögren's Syndrome (SS):** This is a systemic autoimmune disease where the body's own immune cells (lymphocytes) infiltrate and attack the exocrine glands, including the salivary and lacrimal glands . This chronic inflammation leads to progressive destruction of the acinar cells through various mechanisms, including apoptosis, fibrosis, and cytokine-mediated damage, ultimately resulting in irreversible glandular hypofunction [22].
- **Diabetes Mellitus (DM):** Xerostomia in patients with diabetes, particularly when poorly controlled, is multifactorial. It can result from dehydration due to hyperglycemic polyuria (excessive urination), as well as from diabetic autonomic neuropathy that impairs the neural control of salivary glands. The biochemical profile of saliva is also altered; studies have consistently shown that individuals with both type 1 and type 2 diabetes have significantly elevated levels of salivary amylase compared to non-diabetic controls [22].
- **Renal Failure:** Patients with end-stage renal disease (ESRD) frequently experience xerostomia due to a combination of factors, including centrally mediated thirst, fluid restrictions required for their management, and direct uremic effects on salivary gland function. Saliva in these patients serves as a mirror of their systemic metabolic derangement, exhibiting significantly elevated concentrations of urea, creatinine, potassium, and phosphate [22].

The Role of the Laboratory in Differential Diagnosis of xerostomia

A precise diagnosis of the cause of xerostomia is critical for effective management. This requires a combination of

clinical history and targeted laboratory investigations to distinguish between drug-induced and disease-induced etiologies [23].

Differentiating Drug-Induced vs. Disease-Induced Xerostomia

The diagnostic process begins with a meticulous medication reconciliation, including all prescription, over-the-counter, and herbal supplements. A clear temporal relationship the onset of dry mouth symptoms shortly after the initiation of a new medication is a strong indicator of a drug-induced cause. The gold standard for confirmation is observing the resolution of symptoms upon discontinuation or substitution of the suspected agent, a process known as de-challenge/re-challenge. However, if xerostomia persists after medication changes, or if the patient presents with concomitant systemic symptoms such as dry eyes (xerophthalmia), joint pain, rash, or fatigue, an underlying systemic disease like Sjögren's syndrome should be strongly suspected [24].

Autoantibody Testing and Inflammatory Markers

When Sjögren's syndrome is suspected, serological testing is a cornerstone of the diagnostic workup . The most specific laboratory tests involve detecting characteristic autoantibodies [23].

- **Anti-SSA/Ro and Anti-SSB/La:** These are the hallmark autoantibodies for Sjögren's syndrome and are part of the formal classification criteria. They are typically identified through an extractable nuclear antigen (ENA) panel, which is often ordered following a positive antinuclear antibody (ANA) test.
- **Rheumatoid Factor (RF):** While not specific, RF is frequently positive in patients with Sjögren's syndrome [23].

In addition to autoantibodies, markers of systemic inflammation and lymphocyte activation can support the diagnosis and correlate with disease severity:

- **Beta-2-Microglobulin ({\beta}2M):** This protein, shed from activated lymphocytes, is often elevated in the serum of patients with primary Sjögren's syndrome (pSS). Studies have shown that serum {\beta}2M levels are strongly and inversely correlated with salivary flow rates, making it a useful biomarker for assessing the degree of salivary gland dysfunction.
- **Pro-inflammatory Cytokines:** Levels of cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-{\alpha}) are also elevated in pSS and show a significant negative correlation with salivary flow, reflecting the underlying inflammatory process driving the glandular damage [23].

A Multidisciplinary Assessment Framework

A siloed approach to managing xerostomia in the context of polypharmacy is destined for failure. Effective management requires a comprehensive, multidimensional assessment that integrates insights from various disciplines to form a complete, person-centered understanding of the patient's condition. This framework encompasses the patient's psychosocial context, a rigorous medication review, a detailed clinical evaluation of oral and functional status, and objective diagnostic measurements [25].

Psychosocial and Environmental Assessment

The role of the social work specialist of xerostomia is to look beyond the prescription pad and the dental chair to understand the real-world context in which the patient lives. This assessment is foundational, as psychosocial and environmental barriers can render even the most well-designed clinical plan ineffective . A psychosocial assessment is a holistic evaluation of the patient's mental, social, cultural, and developmental needs [26].

Identifying Patient-Level Barriers

Key domains of the assessment focus on identifying barriers that could impede adherence and self-management . This includes evaluating:

- **Health Literacy:** The patient's ability to comprehend their medical conditions, understand the purpose of their medications, and follow complex instructions for both drug regimens and oral hygiene is a critical determinant of outcomes . Low health literacy can lead to misunderstanding and nonadherence [27].
- **Financial Constraints:** The ability to afford medications, co-payments for specialist visits (including dental care, which is often poorly covered), and access to nutritious food must be assessed. Financial hardship can lead to medication non-adherence or the inability to pursue necessary dental treatment [28].
- **Social Support and Isolation:** The assessment identifies the patient's support network, including family, friends, and community ties. Social isolation is a significant risk factor for depression and neglect, and it limits the practical support available for tasks like picking up prescriptions or getting to appointments [29].
- **Transportation and Access:** Practical barriers, such as the lack of reliable transportation, can prevent patients from attending essential medical, pharmacy, and dental appointments [30].

Assessing Caregiver Capacity and Support Networks

For many older adults, a family member or other informal caregiver is integral to their care. The social worker assesses the caregiver's capacity, including their understanding of the patient's conditions and treatment plan, their own level of stress and burnout, and their ability to provide the necessary support for medication administration and daily oral care . This ensures that the care plan is realistic and sustainable for the entire family unit [31].

Integrated Management Strategies

Effective management of polypharmacy and xerostomia in the geriatric population requires a coordinated, multi-

pronged approach that moves beyond symptom palliation to address the root causes of the problem. This integrated strategy involves pharmaceutical interventions to optimize medication regimens, specialized dental care to manage and prevent oral complications, and robust patient support systems to ensure the plan's real-world success. These strategies can be conceptualized in a hierarchical manner: causal interventions (deprescribing), physiological interventions (sialagogues), and palliative/preventive interventions (oral care). No single discipline can operate effectively across all levels, underscoring the necessity of an integrated team.[32]

Pharmaceutical and Deprescribing Interventions

The primary and most impactful intervention for medication-induced xerostomia is to address the causative agents. This is the domain of the clinical pharmacist and prescribing physician, focusing on reducing the overall medication burden and xerogenic load [33].

Strategies for Deprescribing

Deprescribing is defined as the planned and supervised process of discontinuing medications for which the potential harms outweigh the potential benefits within the context of an individual patient's care goals, current level of functioning, and life expectancy . It is a patient-centered process that begins with a comprehensive medication review to identify target medications, particularly those with a high anticholinergic burden or those deemed potentially inappropriate by criteria like STOPP or Beers . The decision to deprescribe is a shared one, made in collaboration with the patient and their caregivers . A critical aspect of successful deprescribing is the method of discontinuation. Many drugs, especially psychotropics and some cardiovascular agents, should not be stopped abruptly. A gradual dose taper is often necessary to prevent withdrawal symptoms or rebound of the underlying condition. A common strategy is to reduce the dose by 25% to 50% over one to four weeks, with close monitoring for any adverse effects or worsening of symptoms.[34]

Therapeutic Substitution with Less-Xerostomic Alternative drugs

When a medication is deemed essential for managing a chronic condition but is causing significant xerostomia, therapeutic substitution is a key strategy . This involves replacing the offending drug with an alternative from the same or a different class that has a lower potential for causing dry mouth. For example:

- In treating depression or neuropathic pain, a highly anticholinergic tricyclic antidepressant (e.g., amitriptyline) could be substituted with a selective serotonin reuptake inhibitor (SSRI) (e.g., sertraline), which generally has a more favorable side effect profile regarding xerostomia [35].
- For managing an overactive bladder, newer, more selective agents or alternative drug classes (e.g., mirabegron, a beta-3 adrenergic agonist) may be considered as substitutes for older, highly anticholinergic drugs like oxybutynin [36].

Pharmacological Stimulation: Sialagogues and Their Systemic Considerations [37-42]

For patients who continue to experience xerostomia despite medication optimization, or for whom deprescribing is not feasible, pharmacological stimulation of residual salivary gland function is an option . The primary agents used are systemic sialagogues, which are muscarinic receptor agonists. A comparison of the two main agents is provided in Table 3.

- **Pilocarpine and Cevimeline:** These drugs stimulate cholinergic receptors on acinar cells to increase saliva production . Pilocarpine is a non-selective muscarinic agonist, while cevimeline exhibits greater selectivity for M1 and M3 receptors, which are predominant in salivary glands . This selectivity may translate to a lower incidence of cardiac (M2-mediated) side effects with cevimeline [37-42].
- **Systemic Considerations in Geriatrics:** The use of these agents in older adults requires caution. As systemic cholinergic agonists, they can cause a range of adverse effects, including sweating, nausea, rhinitis, urinary frequency, and dizziness, which can be particularly problematic in this population . They are contraindicated in patients with uncontrolled asthma, acute iritis, and narrow-angle glaucoma, and should be used with care in those with significant cardiovascular disease or COPD . Treatment should always be initiated at the lowest effective dose and titrated slowly based on patient response and tolerance.

Table 3: Systemic Sialagogues: Clinical Considerations in the Geriatric Population

Agent	Mechanism of Action	Recommended Dosage	Common Adverse Effects in Geriatrics	Key Contraindications/Cautions
Pilocarpine	Non-selective muscarinic receptor agonist	5 mg, 3-4 times daily	Sweating, nausea, rhinitis, urinary frequency, flushing, dizziness	Uncontrolled asthma, narrow-angle glaucoma, severe cardiac disease
Cevimeline	Selective M1/M3 muscarinic receptor agonist	30 mg, 3 times daily	Sweating (less than pilocarpine), nausea, diarrhea, visual disturbance	Uncontrolled asthma, narrow-angle glaucoma; use with

Agent	Mechanism of Action	Recommended Dosage	Common Adverse Effects in Geriatrics	Key Contraindications/Cautions
				cautions in patients with cardiac history

Dental and Palliative Oral Care

The dental team plays a pivotal role in managing the devastating oral consequences of xerostomia and in providing palliative relief from the symptoms of dry mouth. This involves both aggressive prevention and active management of complications.

Management of Oral Complications: Intensive Caries Prevention

Given the extremely high caries risk associated with hyposalivation, a standard preventive regimen is insufficient. An intensive protocol is required:

- **High-Fluoride Agents:** Prescription-strength, high-concentration fluoride toothpaste (5000 ppm fluoride) should be recommended for daily use in place of standard toothpaste [45]. In-office application of high-concentration fluoride varnish (22,600 ppm fluoride) should be performed at frequent intervals, such as every three months, to provide a sustained topical fluoride reservoir .[46]
- **Calcium Phosphate Technologies:** Products containing casein phosphopeptide-amorphous calcium phosphate (CPP-ACP), such as MI Paste or GC Tooth Mousse, are valuable adjuncts. CPP-ACP stabilizes calcium and phosphate ions, making them bioavailable at the tooth surface. Under acidic conditions, these ions are released, buffering the acid and promoting remineralization by providing the necessary mineral building blocks that are deficient in hyposalivation . Formulations that combine CPP-ACP with fluoride (CPP-ACPF) may offer a synergistic effect .

Palliative Management: Salivary Substitutes and Oral Lubricants

For symptomatic relief, a variety of over-the-counter palliative products can be recommended. These products do not stimulate saliva production but aim to lubricate and moisten the oral tissues, providing temporary comfort.[47]

- **Saliva Substitutes:** These are available as sprays, gels, and rinses. Their formulations typically contain lubricating and viscosity-enhancing agents such as carboxymethylcellulose (CMC), hydroxyethyl cellulose, glycerin, xanthan gum, or, less commonly, animal-derived mucins .
- **Oral Lubricants:** Simple measures can also be effective. Patients can be advised to use lip balms to prevent chapped lips and to apply a small amount of vegetable oil or another edible oil to the oral mucosa for lubrication, especially at night .[48]
- **Effectiveness:** It is important to manage patient expectations, as the evidence for the efficacy of many commercial saliva substitutes is weak. Many studies and clinical observations suggest that they are often no more effective than frequent sips of water and that their effect is short-lived, requiring frequent reapplication . Their primary role is palliative comfort rather than therapeutic effect.

Patient Education on Dietary Modifications

Dietary counseling is a critical component of the dental management plan. The dental team should educate the patient on the importance of:[49]

- **Avoiding Cariogenic and Acidic Foods:** Limiting the intake of sugary and sticky foods that promote caries, as well as acidic foods and beverages (e.g., soft drinks, citrus juices) that can cause dental erosion, which is accelerated in a low-saliva environment .
- **Sipping Water:** Encouraging frequent sipping of water throughout the day, especially during meals, to aid in chewing, bolus formation, and swallowing .
- **Avoiding Oral Irritants:** Advising against the use of tobacco, caffeine, and alcohol, including alcohol-containing mouthwashes, as these can exacerbate the sensation of dryness and irritate the oral mucosa .[50]

Patient Support and System Navigation

The roles of nursing and social work serve as the crucial "connective tissue" that binds the clinical recommendations of the pharmacist, physician, and dentist into a coherent and executable plan. They are responsible for translating the plan into real-world patient behaviors and addressing the socio-environmental factors that determine its ultimate success.

The Nursing Role

Nurses are often the most frequent point of contact for the patient and are central to implementation, education, and monitoring . Their role includes:[51]

- **Patient Education and Reinforcement:** Teaching and reinforcing proper oral hygiene techniques (e.g., brushing, flossing), instructing on the correct use of prescribed fluoride agents and palliative products, and providing ongoing education about beneficial dietary and hydration habits.
- **Monitoring and Follow-up:** Regularly assessing the patient's symptoms, monitoring for the development of oral or systemic complications, and evaluating the impact of xerostomia on ADLs. This ongoing assessment provides vital feedback to the entire team, allowing for timely adjustments to the care plan .[52]

The Social Work Role

The social worker functions as a patient advocate and system navigator, focusing on dismantling the psychosocial and environmental barriers to care that were identified during the initial assessment. Key responsibilities include:

- **Connecting Patients to Resources:** Actively linking patients to essential support services. This may involve enrolling them in medication assistance programs to improve affordability of less-xerostomic drugs, finding low-cost or public dental clinics, and connecting them with community programs like Meals on Wheels or transportation services .
- **Care Coordination and Advocacy:** Facilitating clear communication between the patient, their family, and the various members of the multidisciplinary team. The social worker ensures that information flows freely between providers and that the patient's voice, values, and goals are central to all care planning decisions . They advocate for the patient's needs within the complex healthcare system, ensuring that the integrated plan is not just created but successfully implemented.[53]

Emerging Technologies and Future Directions

While current management strategies focus on risk reduction and symptom palliation, the future of xerostomia treatment is moving toward restorative and personalized medicine. Advances in biotechnology, diagnostics, and care delivery models promise to shift the paradigm from managing a chronic condition to potentially restoring function and preventing disease with greater precision.

Biotechnological Innovations

Cutting-edge research in biotechnology is exploring novel ways to repair or replace damaged salivary gland tissue, offering hope for patients with irreversible hypofunction.[54]

Tissue Engineering: Development of Artificial Salivary Glands

For patients whose salivary glands have been irreversibly damaged by radiation or advanced autoimmune disease, tissue engineering represents a potential long-term solution . This interdisciplinary field aims to regenerate functional salivary gland tissue by combining salivary gland stem/progenitor cells or pluripotent stem cells with biodegradable scaffolds and growth factors . The goal is to create a bioengineered "organoid" or artificial salivary gland that can be implanted to produce saliva. While still largely in the preclinical phase, studies in animal models have demonstrated successful regeneration of functional salivary tissue through the orthotopic transplantation of these bioengineered constructs, representing a significant step toward a curative therapy . Another innovative approach under investigation involves a specialized dental implant designed to harvest and filter interstitial fluid from the jawbone, releasing it into the oral cavity as a continuous supply of artificial saliva .[55]

Novel Drug Delivery Systems for Sialagogues or Lubricants

A significant limitation of current systemic sialagogues like pilocarpine is their widespread, non-targeted action, which leads to systemic side effects . To address this, researchers are developing novel drug delivery systems designed for localized, sustained release within the oral cavity . These technologies include:

- **Mucoadhesive Formulations:** Gels, films, and nanoparticles that adhere to the oral mucosa can provide a prolonged release of lubricating agents or sialagogues directly at the target site . This approach could enhance the duration of palliative relief and potentially deliver drugs like pilocarpine locally, thereby minimizing systemic absorption and adverse effects .[56]
- **Nanotechnology-Based Systems:** Liposomes and nanospheres are being explored to encapsulate drugs like pilocarpine, which can increase their residence time on oral or ocular surfaces and potentially facilitate more efficient delivery into target cells .

Gene Therapy for Acquired Salivary Gland Hypofunction

Gene therapy is one of the most promising restorative strategies, particularly for radiation-induced xerostomia. The primary approach involves using a benign viral vector, typically an adeno-associated virus (AAV), to deliver a therapeutic gene into the surviving ductal cells of a damaged salivary gland . The most studied target gene is AQP1, which encodes the water channel protein aquaporin-1 . Radiation therapy primarily destroys the water-secreting acinar cells, but often leaves the ductal cells intact. These ductal cells, however, lack the necessary water channels to produce saliva. By transferring the AQP1 gene, the ductal cells are re-engineered to transport water, effectively transforming them into fluid-secreting cells . A first-in-human Phase 1 clinical trial of AAV2-AQP1 for radiation-induced xerostomia demonstrated both safety and efficacy, with a subset of patients experiencing significant, long-lasting increases in saliva flow and subjective improvement in dry mouth symptoms . Research is now expanding to explore this technology for treating xerostomia associated with Sjögren's syndrome [57] .

Advances in Diagnostics and Pharmacogenomics

The future of management also lies in better prediction and earlier detection, moving from a reactive to a proactive model of care.[58]

Salivary Proteomics: Novel Biomarkers for Early Detection and Monitoring

Saliva itself is a rich diagnostic fluid, containing thousands of proteins that can reflect both local and systemic health . Salivary proteomics, which uses advanced techniques like mass spectrometry to analyze the entire protein content of saliva, is an emerging field for non-invasive biomarker discovery. For conditions like Sjögren's syndrome, researchers

have identified distinct "protein signatures"—patterns of up- and down-regulated proteins (including inflammatory markers, cystatins, and mucins)—that can differentiate patients from healthy controls, even in preclinical stages before symptoms are fully apparent . The development of these proteomic biomarkers could lead to simple, chairside diagnostic tests for the early detection of salivary gland dysfunction, allowing for intervention before irreversible damage occurs [59] .

Pharmacogenomics: Predicting Individual Risk for Drug-Induced Xerostomia

Pharmacogenomics (PGx) is the study of how a
n individual's genetic makeup influences their response to drugs. It is the foundation of personalized medicine, aiming to predict who will benefit from a medication, who will not respond, and who will experience adverse effects . Genetic variations in genes that code for drug-metabolizing enzymes (e.g., the CYP450 family), drug transporters, or drug targets can significantly alter a drug's pharmacokinetics and pharmacodynamics .

While the field is most advanced for drugs like warfarin and certain antidepressants, its application to drug-induced xerostomia holds significant potential . By identifying genetic variants that predispose an individual to be a "poor metabolizer" of a known xerostomic drug, clinicians could predict a heightened risk of that adverse effect before the drug is ever prescribed. This would allow for proactive selection of an alternative medication, moving from a "trial-and-error" approach to a "predict-and-prevent" strategy, thereby personalizing polypharmacy management to minimize harm .[60]

Future Models of Care

Alongside technological advances, new models of care are being developed and tested to deliver more effective, integrated, and accessible geriatric care.

Efficacy of Interdisciplinary Geriatric "Deprescribing" Clinics

There is a growing body of evidence supporting the efficacy of dedicated, interdisciplinary clinics focused on medication optimization and deprescribing for older adults. These clinics typically operate with a core team of a geriatrician, a clinical pharmacist, and a nurse, who collaboratively conduct comprehensive assessments and create individualized deprescribing plans. Clinical trials have shown that interventions delivered through such models are effective. For example, a pilot study of the THRIVE (Targeting Hospitalization Risks in Vulnerable Elders) clinic demonstrated significant reductions in total medication count, tablet burden, and the number of PIMs in a population of older patients with frequent hospital admissions . Systematic reviews and meta-analyses further support this, with intensive, pharmacist-led interventions integrated into collaborative care models showing a significant increase in effective deprescribing and a meaningful reduction in the number of medications.[61]

The Role of Telehealth in Multidisciplinary Follow-up

Telehealth has emerged as a powerful tool to overcome many of the traditional barriers to geriatric care, such as mobility limitations, transportation issues, and geographic distance. Its application in a multidisciplinary model for managing polypharmacy and its complications is particularly promising:[62]

- **Enhanced Access and Coordination:** Telehealth platforms enable virtual consultations, allowing patients, caregivers, and multiple providers (e.g., geriatrician, pharmacist, social worker) to connect simultaneously from different locations. This facilitates the kind of real-time, interdisciplinary communication and shared decision-making that is essential for integrated care but often difficult to schedule in person .
- **Remote Monitoring and Management:** Telehealth can be used for remote medication reviews, patient education, and follow-up assessments of symptoms and functional status . This allows for more frequent, convenient check-ins to monitor the effects of deprescribing, adjust care plans, and provide ongoing support, thereby enhancing continuity of care for patients with chronic conditions .[63]

The convergence of these future directions restorative biotechnologies, predictive diagnostics, and integrated, accessible care models paints an optimistic picture. The management of polypharmacy and xerostomia is poised to evolve from a reactive, palliative discipline into a proactive, personalized, and potentially curative field of geriatric medicine.

CONCLUSION

The convergence of polypharmacy and xerostomia in the geriatric population represents a significant and growing public health challenge. This review has synthesized a broad spectrum of evidence to demonstrate that this dual burden is not an inevitable consequence of aging but a complex, iatrogenic syndrome rooted in high medication exposure, compounded by age-related physiological vulnerabilities and social determinants of health. The resulting cascade of oral and systemic complications profoundly degrades quality of life and imposes a substantial economic burden. Addressing this challenge effectively requires a fundamental shift away from fragmented, discipline-specific care toward a fully integrated, multidisciplinary, and person-centered model.

REFERENCES

1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC geriatrics. 2017 Oct 10;17(1):230.
2 Hoel RW, Connolly RM, Takahashi PY. Polypharmacy management in older patients. InMayo Clinic Proceedings 2021 Jan 1 (Vol. 96, No. 1, pp. 242-256). Elsevier.
3. López-Pintor RM, Ramírez Martínez-Acitores L, Serrano Valle J, González-Serrano J, Casañas E, de Arriba L, Hernández G. Xerostomia and hyposalivation. InOral Health and Aging 2022 Feb 1 (pp. 85-108). Cham: Springer International Publishing.
4. Anil S, Vellappally S, Hashem M, Preethanath RS, Patil S, Samaranayake LP. Xerostomia in geriatric patients: a burgeoning global concern. Journal of investigative and clinical dentistry. 2016 Feb;7(1):5-12.
5. Okuyama K, Yanamoto S. Saliva in balancing oral and systemic health, oral cancer, and beyond: a narrative review. Cancers. 2024 Dec 23;16(24):4276.
6. Tschoppe P, Wolgin M, Pischon N, Kielbassa AM. Etiologic factors of hyposalivation and consequences for oral health. Quintessence international. 2010 Apr 1;41(4).
7. López-Pintor RM, Ramírez Martínez-Acitores L, Serrano Valle J, González-Serrano J, Casañas E, de Arriba L, Hernández G. Xerostomia and hyposalivation. InOral Health and Aging 2022 Feb 1 (pp. 85-108). Cham: Springer International Publishing.
8. Ginsberg S. Xerostomia: An Interdisciplinary Approach to Managing Dry Mouth. CRC Press; 2024 Jun 1.
9. Ijaz MH. The Burden of Oral Diseases in Aging Populations: Implications for Public Health Policy. Journal of Dental Care. 2024 Oct 10;1(1):11-20.
10. Chae J, Cho HJ, Yoon SH, Kim DS. The association between continuous polypharmacy and hospitalization, emergency department visits, and death in older adults: a nationwide large cohort study. Frontiers in Pharmacology. 2024 Jul 31;15:1382990.
11. Iqbal A, Richardson C, Iqbal Z, O'Keefe H, Hanratty B, Matthews FE, Todd A. Are there socioeconomic inequalities in polypharmacy among older people? A systematic review and meta-analysis. BMC geriatrics. 2023 Mar 18;23(1):149.
12. Arany S, Kopycka-Kedzierawski DT, Caprio TV, Watson GE. Anticholinergic medication: Related dry mouth and effects on the salivary glands. Oral surgery, oral medicine, oral pathology and oral radiology. 2021 Dec 1;132(6):662-70.
13. Barbe AG. Medication-induced xerostomia and hyposalivation in the elderly: culprits, complications, and management. Drugs & aging. 2018 Oct;35(10):877-85.
14. Ramírez L, Sánchez I, Muñoz M, Martínez–Acitores ML, Garrido E, Hernández G, López-Pintor RM. Risk factors associated with xerostomia and reduced salivary flow in hypertensive patients. Oral diseases. 2023 Apr;29(3):1299-311.
15. Cheah HL, Gray M, Aboelmagd S, Barmak AB, Arany S. Anticholinergic medication and caries status predict xerostomia under 65. Dentistry Journal. 2023 Mar 23;11(4):87.
16. Silva IV, de Figueiredo RC, Rios DR. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. International journal of molecular sciences. 2019 Jul 14;20(14):3458.
17. Gandhi P, Saxena A, Pai K, Ongole R. Oral manifestations of psychotropic drugs on the oral cavity: observational study. The Journal of Contemporary Dental Practice. 2022 Jul 11;23(4):443-6.
18. Peacock S. Medications Used for the Respiratory System. InUnderstanding Pharmacology in Nursing Practice 2020 Feb 7 (pp. 283-317). Cham: Springer International Publishing.
19. Mansour A, Alrayes HA, Alabid MS, Aljoufi AB, Alruwaili AL, Shammar SF, Alsuhayyan RA, Issrani R. Navigating Dental Care and Oral Health Management Challenges in Sjögren's Syndrome: A Comprehensive Case Report with Literature Review. The Open Dentistry Journal. 2025 Feb 13;19(1).
20. Chibly AM, Aure MH, Patel VN, Hoffman MP. Salivary gland function, development, and regeneration. Physiological reviews. 2022 May 17.
21. Proctor GB, Shaalan AK. Salivary gland secretion. InPhysiology of the Gastrointestinal Tract 2018 Jan 1 (pp. 813-830). Academic Press.
22. Hou F, Cui Y, Ye L, Chen F, Wu C, Meng Y, Yuan P, Qiu X, Feng X, Jiang L. Metabolomic insights into idiopathic xerostomia: the central role of caffeine metabolism in salivary biochemistry. Archives of Oral Biology. 2025 Jan 1;169:106102.
23. Häusler RJ, Ritschard J, N'Guyen VT, Montandon PB. Differential diagnosis of xerostomia by quantitative salivary gland scintigraphy. Annals of Otology, Rhinology & Laryngology. 1977 May;86(3):333-41.
24. Jha AN, Gaikwad VR. Foundations of Patient Safety an Essential Approach to Medication History Conversations. International Journal of Nursing Education and Research. 2025 May 20;13(2):64-70.
25. Ginsberg S. Xerostomia: An Interdisciplinary Approach to Managing Dry Mouth. CRC Press; 2024 Jun 1.
26. Cases IU. Transforming Oral Health Care Through Interprofessional Education.
27. Firmino RT, Ferreira FM, Paiva SM, Granville-Garcia AF, Fraiz FC, Martins CC. Oral health literacy and associated oral conditions: A systematic review. The Journal of the American Dental Association. 2017 Aug

1;148(8):604-13.
28. Urbanos Garrido, R.M., Peña Longobardo, L.M., Comendeiro Malooe, M., Oliva, J., Ridao López, M. and Bernal Delgado, E., 2021. Can people afford to pay for health care? New evidence on financial protection in Spain.
29. Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. Journal of clinical oncology. 2006 Mar 1;24(7):1105-11.
30. Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Community Health. 2013 Oct;38(5):976-93. doi: 10.1007/s10900-013-9681-1. PMID: 23543372; PMCID: PMC4265215.
31. McGilton KS, Vellani S, Yeung L, Chishtie J, Commisso E, Ploeg J, Andrew MK, Ayala AP, Gray M, Morgan D, Chow AF. Identifying and understanding the health and social care needs of older adults with multiple chronic conditions and their caregivers: a scoping review. BMC geriatrics. 2018 Oct 1;18(1):231.
32. Friedman SM, editor. Geriatrics, Lifestyle Medicine and Healthy Aging: A Practical Guide. CRC Press; 2025 Sep 30.
33. Ito K, Izumi N, Funayama S, Nohno K, Katsura K, Kaneko N, Inoue M. Characteristics of medication-induced xerostomia and effect of treatment. PLoS One. 2023 Jan 12;18(1):e0280224. doi: 10.1371/journal.pone.0280224. PMID: 36634078; PMCID: PMC9836311.
34. Duncan P, Duerden M, Payne RA. Deprescribing: a primary care perspective. Eur J Hosp Pharm. 2017 Jan;24(1):37-42. doi: 10.1136/ejhpharm-2016-000967. PMID: 31156896; PMCID: PMC6451545.
35. Wolff A, Joshi RK, Ekström J, Aframian D, Pedersen AM, Proctor G, Narayana N, Villa A, Sia YW, Aliko A, McGowan R, Kerr AR, Jensen SB, Vissink A, Dawes C. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 2017 Mar;17(1):1-28. doi: 10.1007/s40268-016-0153-9. PMID: 27853957; PMCID: PMC5318321.
36. Bragg R, Hebel D, Vouri SM, Pitlick JM. Mirabegron: a Beta-3 agonist for overactive bladder. Consult Pharm. 2014 Dec;29(12):823-37. doi: 10.4140/TCP.n.2014.823. PMID: 25521658; PMCID: PMC4605389.
37. Barbe AG. Medication-induced xerostomia and hyposalivation in the elderly: culprits, complications, and management. Drugs & aging. 2018 Oct;35(10):877-85.
39. Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clinical Journal of the American Society of Nephrology. 2010 Feb 1;5(2):314-27.
40. Mangoni AA, Woodman RJ, Jarmuzewska EA. Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far. Expert Opinion on Drug Metabolism & Toxicology. 2025 May 12:1-9.
41. Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clinical Pharmacokinetics. 2025 Mar;64(3):335-67.
42. Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clinical Pharmacokinetics. 2025 Mar;64(3):335-67.
43. Ito K, Izumi N, Funayama S, Nohno K, Katsura K, Kaneko N, Inoue M. Characteristics of medication-induced xerostomia and effect of treatment. PLoS One. 2023 Jan 12;18(1):e0280224.
44. Avelino SO, Neves RM, Sobral-Silva LA, Tango RN, Federico CA, Vegian MR, de Almeida-Silva LA, Kaminagakura E, Amorim JB, Vasconcellos LM. Evaluation of the effects of radiation therapy on muscle contractibility and skin healing: An experimental study of the cancer treatment implications. Life. 2023 Aug 30;13(9):1838.
45. Guimarães DD, Parro YM, Muller HS, Coelho EB, Martins VD, Santana R, Lia ÉN. Xerostomia and dysgeusia in the elderly: prevalence of and association with polypharmacy. Brazilian Journal of Oral Sciences. 2023 Mar 20;22:e236637.
46. Guimarães DD, Parro YM, Muller HS, Coelho EB, Martins VD, Santana R, Lia ÉN. Xerostomia and dysgeusia in the elderly: prevalence of and association with polypharmacy. Brazilian Journal of Oral Sciences. 2023 Mar 20;22:e236637.
47. Lee B, Chien AL. 326 Utilization of biosimilars versus reference drugs for treatment of dermatological conditions. Journal of Investigative Dermatology. 2024 Aug 1;144(8):S56.
48 Simoni-Wastila L, Yang HW. Drug abuse and addiction in elderly. Drug abuse and addiction in medical illness: Causes, consequences and treatment. 2012 May 31:455-65.
49. Kia SJ, Basirat M, Soleimani R, Tadayon K, Najar-Karimi F. Association of Psychological Factors with Burning Mouth Syndrome in Psychiatric Diseases. Journal of Research in Dental and Maxillofacial Sciences. 2024 Sep 10;9(3):184-92.
50. Kim YJ. Xerostomia and its cellular targets. International journal of molecular sciences. 2023 Mar 10;24(6):5358.
51. Yeoh SC. Adverse drug reactions in the orofacial complex. Pathological Basis of Oral and Maxillofacial Diseases. 2025 Jan 8:377-405.
52. Kim YJ. Xerostomia and its cellular targets. International journal of molecular sciences. 2023 Mar 10;24(6):5358.
53. Sharma D, Higgins O, Sawicki A, Ramamurthy P, Field B, Hussein P, Singh K, Ranjitkar S. Oral Health in

Individuals with Severe Mental Illness on Second-Generation Antipsychotics—A Scoping Review. Journal of Oral Pathology & Medicine. 2025 May 6.
54. Gregory PJ, Morrow LE, Malesker MA. Medication Therapy Management in Hospitalized Elderly Patients: A Focus on OTC Agents.
55. Stanescu, I., et al. (2024). Dry mouth in Sjögren's syndrome is independent of serological and inflammatory parameters. MDPI. Retrieved from https://www.mdpi.com/2076-3417/14/13/5451
56. Mathews SA, Kurien BT, Scofield RH. Oral manifestations of Sjögren's syndrome. Journal of dental research. 2008 Apr;87(4):308-18.
57. D'Agostino C, Elkashty OA, Chivasso C, Perret J, Tran SD, Delporte C. Insight into salivary gland aquaporins. Cells. 2020 Jun 25;9(6):1547.
58. Tang Y, Zhou Y, Wang X, Che N, Tian J, Man K, Rui K, Peng N, Lu L. The role of epithelial cells in the immunopathogenesis of Sjögren's syndrome. Journal of Leukocyte Biology. 2024 Jan;115(1):57-67.
59. Grootveld M, Percival BC, Page G, Hunwin K, Bhogadia M, Chan W, Edgar M. Updates and original case studies focused on the NMR-linked metabolomics analysis of human oral fluids Part II: Applications to the diagnosis and prognostic monitoring of oral and systemic cancers. Metabolites. 2022 Aug 24;12(9):778.
60. Mhatre S, Srichand R, Sethumadhavan J, Mishra PB, Patil SD, Chavan RS, Joshi M, Shetty U, Chavan R. Dry mouth dilemma: a comprehensive review of xerostomia in complete denture wearers. Cureus. 2024 Apr 18;16(4).
61. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Sjögren's syndrome. The Autoimmune Diseases. 2014 Jan 1:495-510.
62. Shetty SR, Bhowmick S, Castelino R, Babu S. Drug induced xerostomia in elderly individuals: An institutional study. Contemporary clinical dentistry. 2012 Apr 1;3(2):173-5.
63. Ben-Omran MO, Livinski AA, Kopycka-Kedzierawski DT, Boroumand S, Williams D, Weatherspoon DJ, Iafolla TJ, Fontelo P, Dye BA. The use of teledentistry in facilitating oral health for older adults: a scoping review. The Journal of the American Dental Association. 2021 Dec 1;152(12):998-1011.